Competitive Technologies announced today that patent number 6,808,561 has been issued by the US Patent Office for Dr. Brian R. Genge's nanotechnology bone biomaterial developed at the Universi
Patent litigation remains the most commonly used generic defense strategy among pharmaceutical companies. 71% of drug companies have used legal battles to defend their patents in the past three years, according to research from pharmaceutical business
Morphotek announced today the issuance of United States Patent 6,808,894 covering the generation of genetically enhanced antibody producer cell lines. The issued patent covers the use of the
Hydroderm announced today that after years of clinical research, Hydroderm's exclusive Collagen Infusion Delivery System was granted a U.S. patent. The system delivers whole molecules of mar
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Dir
Morphotek announced today the issuance of United States Patent 6,825,038 covering the regulation of mismatch repair (MMR), a powerful process for generating functional diversity in mammalian cells,
Biolase Technology today announced that it has been granted a new U.S. patent protecting key areas related to its laser pulse technology. U.S. Patent No. 6,821,272, granted by the U.S. Patent
Tercica announced today the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Vir
Genaissance Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming methods for identifying correlations between the safety and effi
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applic
Date: Wednesday, 30-Aug-2006
Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetically Altered Antigens."These patents cover inventions regarding the Company's whole genome evolution platform technologies that can improve the pharmacologic activity of therapeutic biologicals as well as cell hosts for improved product manufacturing.
Patent 6,921,666 covers the use of mismatch repair (MMR) inhibitors for generating functional diversity in yeast, to yield sibling cells exhibiting desirable phenotypes for target discovery, drug screening and/or product development. Patent 6,737,268 covers the use of MMR inhibitors in vaccine production cell lines to yield sibling cells producing evolved vaccines with increased immunogenic activity and/or enhanced pharmacokinetic properties. These grants provide Morphotek the exclusive right to employ these technologies in 20 designated countries across the European Union.
The MMR pathway is a highly conserved process that all living organisms use to repair naturally occurring mutations that occur during DNA replication. The selective regulation of the MMR function via morphogenics results in an unbiased, undirected and accelerated rate of genetic evolution within a living host organism. Morphotek employs morphogenics to discover and develop novel proteins and antibodies for diagnosing and treating cancer, inflammatory and infectious diseases. The technology has been validated through research collaborations with premier academic and corporate partners including Amgen, Centocor, John Wayne Cancer Institute, GlaxoSmithKline, Ludwig Institute for Cancer Research, National Cancer Institute, Novo Nordisk, Protein Design Labs, Wistar Institute, Wyeth and the U.S. Army Medical Research Institute of Infectious Diseases as well as through its application to internal development candidates "MORAb-003" and "MORAb-009" currently in clinical development for the treatment of ovarian and pancreatic cancer, respectively.
http://www.morphotek.com/